+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

NovoCure Ltd (NVCR) - Product Pipeline Analysis, 2018 Update

  • ID: 4042945
  • Company Profile
  • 55 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Ergomed Plc
  • Oxford BioMedica Plc
  • Vernalis Plc
  • MORE
Summary

NovoCure Ltd (NovoCure) is an drug company that offers development and commercialization of novel therapies for tumor treating fields. The company’s pipeline products find application in cancer indications such as malignant melanoma, hepatocellular carcinoma, ovarian cancer, breast cancer and small cell lung cancer, among others. It also offers provides products for other indications such as glioblastoma and diagnosed glioblastoma, among others. Novocure owns and operates a research centre in Haifa, Israel; and operates along with its subsidiaries located in the US; Berlin, and Germany. The company has its operations in Japan and Switzerland. NovoCure is headquartered in St. Helier, the UK.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company NovoCure Ltd
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Ergomed Plc
  • Oxford BioMedica Plc
  • Vernalis Plc
  • MORE
NovoCure Ltd Company Overview
NovoCure Ltd Company Snapshot
NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview
NovoCure Ltd – Pipeline Analysis Overview
NovoCure Ltd - Key Facts
NovoCure Ltd - Major Products and Services
NovoCure Ltd Pipeline Products by Development Stage
NovoCure Ltd Ongoing Clinical Trials by Trial Status
NovoCure Ltd Pipeline Products Overview
Optune - Brain Metastasis
Optune - Brain Metastasis Product Overview
Optune - Brain Metastasis Clinical Trial
Optune - Breast Cancer
Optune - Breast Cancer Product Overview
Optune - Cervical Cancer
Optune - Cervical Cancer Product Overview
Optune - Colorectal Carcinoma
Optune - Colorectal Carcinoma Product Overview
Optune - Gastric Adenocarcinoma
Optune - Gastric Adenocarcinoma Product Overview
Optune - Hepatocellular Carcinoma
Optune - Hepatocellular Carcinoma Product Overview
Optune - Malignant Melanoma
Optune - Malignant Melanoma Product Overview
Optune - Mesothelioma
Optune - Mesothelioma Product Overview
Optune - Mesothelioma Clinical Trial
Optune - Non - Small Cell Lung Cancer
Optune - Non - Small Cell Lung Cancer Product Overview
Optune - Ovarian Cancer
Optune - Ovarian Cancer Product Overview
Optune - Ovarian Cancer Clinical Trial
Optune - Pancreatic Cancer
Optune - Pancreatic Cancer Product Overview
Optune - Pancreatic Cancer Clinical Trial
Optune - Pediatric Glioma
Optune - Pediatric Glioma Product Overview
Optune - Pediatric Glioma Clinical Trial
Optune - Prostate Cancer
Optune - Prostate Cancer Product Overview
Optune - Renal Adenocarcinoma
Optune - Renal Adenocarcinoma Product Overview
Optune - Squamous Non-Small Cell Lung Cancer
Optune - Squamous Non-Small Cell Lung Cancer Product Overview
Optune - Urinary Transitional Cell Carcinoma
Optune - Urinary Transitional Cell Carcinoma Product Overview
Optune Plus Bevacizumab - Recurrent Glioblastoma
Optune Plus Bevacizumab - Recurrent Glioblastoma Product Overview
Optune With Marizomib And Temozolomide - Glioblastoma
Optune With Marizomib And Temozolomide - Glioblastoma Product Overview
NovoCure Ltd - Key Competitors
NovoCure Ltd - Key Employees
NovoCure Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
NovoCure Ltd, Recent Developments
Jul 02, 2018: Novocure Names Pritesh Shah As Chief Commercial Officer
Jun 04, 2018: Novocure to Present INNOVATE-3 Phase 3 Pivotal Trial Design in Recurrent Ovarian Cancer at the American Society of Clinical Oncology Annual Meeting 2018
May 31, 2018: Novocure Announces Changes to Its Board of Directors
May 28, 2018: Update on Mithra and Mayne Pharma’s Vaginal Contraceptive Ring Opportunity
Apr 26, 2018: Novocure Reports First Quarter 2018 Financial Results and Provides Company Update
Apr 17, 2018: Novocure Reports Positive Top-line Results from STELLAR Phase 2 Pilot Trial in Mesothelioma
Apr 13, 2018: Data on Tumor Treating Fields to Be Presented at American Association for Cancer Research Annual Meeting
Mar 20, 2018: NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma
Mar 15, 2018: Novocure Announces 35 Presentations on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2018
Feb 22, 2018: Novocure Announces Fourth Quarter and Full Year 2017 Financial Results
Appendix
Methodology
About
Contact
Disclaimer

List of Tables
NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview
NovoCure Ltd Pipeline Products by Equipment Type
NovoCure Ltd Pipeline Products by Indication
NovoCure Ltd Ongoing Clinical Trials by Trial Status
NovoCure Ltd, Key Facts
NovoCure Ltd, Major Products and Services
NovoCure Ltd Number of Pipeline Products by Development Stage
NovoCure Ltd Pipeline Products Summary by Development Stage
NovoCure Ltd Ongoing Clinical Trials by Trial Status
NovoCure Ltd Ongoing Clinical Trials Summary
Optune - Brain Metastasis - Product Status
Optune - Brain Metastasis - Product Description
Optune - Brain Metastasis - A Phase II Randomized Study of TTField Therapy (150 kHz) Versus Supportive Care in Non-small Cell Lung Cancer Patients with 1-5 Brain Metastases Following Optimal Standard Local Treatment
Optune - Brain Metastasis - Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
Optune - Brain Metastasis - Pivotal, Open-label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) (150kHz) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC)
Optune - Breast Cancer - Product Status
Optune - Breast Cancer - Product Description
Optune - Cervical Cancer - Product Status
Optune - Cervical Cancer - Product Description
Optune - Colorectal Carcinoma - Product Status
Optune - Colorectal Carcinoma - Product Description
Optune - Gastric Adenocarcinoma - Product Status
Optune - Gastric Adenocarcinoma - Product Description
Optune - Hepatocellular Carcinoma - Product Status
Optune - Hepatocellular Carcinoma - Product Description
Optune - Malignant Melanoma - Product Status
Optune - Malignant Melanoma - Product Description
Optune - Mesothelioma - Product Status
Optune - Mesothelioma - Product Description
Optune - Mesothelioma - A Phase II Trial of Pemetrexed and Cisplatin or Carboplatin in Combination with TTFields (150 kHz) as First-line Treatment in Malignant Pleural Mesothelioma
Optune - Non - Small Cell Lung Cancer - Product Status
Optune - Non - Small Cell Lung Cancer - Product Description
Optune - Ovarian Cancer - Product Status
Optune - Ovarian Cancer - Product Description
Optune - Ovarian Cancer - A Phase III Pivotal Study of Tumor Treating Fields Concomitant with Weekly Paclitaxel in the Treatment of Platinum-resistant Ovarian Cancer: INNOVATE-3
Optune - Ovarian Cancer - An Open Label Pilot Study of the NovoTTF-100L(O) System (NovoTTF Therapy) (200 kHz) Concomitant with Weekly Paclitaxel for Recurrent Ovarian Carcinoma
Optune - Pancreatic Cancer - Product Status
Optune - Pancreatic Cancer - Product Description
Optune - Pancreatic Cancer - A Phase II Study of TTFields (150 kHz) Concomitant with Gemcitabine and TTFields Concomitant with Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma
Optune - Pancreatic Cancer - PANOVA - 3: A Phase III Study of TTFields with Gemcitabine and Nab-paclitaxel for Front - Line Treatment of Locally Advanced Pancreatic Adenocarcinoma (LAPC)
Optune - Pediatric Glioma - Product Status
Optune - Pediatric Glioma - Product Description
Optune - Pediatric Glioma - A Phase I Trial of the Optune NovoTTF-200A System with and without Concomitant Temozolomide and Bevacizumab in Pediatric Patients with High-grade Glioma (HUMC 1612)
Optune - Pediatric Glioma - Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-grade Glioma and Ependymoma
Optune - Prostate Cancer - Product Status
Optune - Prostate Cancer - Product Description
Optune - Renal Adenocarcinoma - Product Status
Optune - Renal Adenocarcinoma - Product Description
Optune - Squamous Non-Small Cell Lung Cancer - Product Status
Optune - Squamous Non-Small Cell Lung Cancer - Product Description
Optune - Urinary Transitional Cell Carcinoma - Product Status
Optune - Urinary Transitional Cell Carcinoma - Product Description
Optune Plus Bevacizumab - Recurrent Glioblastoma - Product Status
Optune Plus Bevacizumab - Recurrent Glioblastoma - Product Description
Optune With Marizomib And Temozolomide - Glioblastoma - Product Status
Optune With Marizomib And Temozolomide - Glioblastoma - Product Description
NovoCure Ltd, Key Employees
NovoCure Ltd, Subsidiaries
Glossary

List of Figures
NovoCure Ltd Pipeline Products by Equipment Type
NovoCure Ltd Pipeline Products by Development Stage
NovoCure Ltd Ongoing Clinical Trials by Trial Status
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Ergomed Plc
  • Oxford BioMedica Plc
  • Vernalis Plc
Note: Product cover images may vary from those shown
Adroll
adroll